These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17979029)

  • 1. Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases.
    Wittig BM
    Curr Opin Investig Drugs; 2007 Nov; 8(11):947-54. PubMed ID: 17979029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.
    Elliott M; Benson J; Blank M; Brodmerkel C; Baker D; Sharples KR; Szapary P
    Ann N Y Acad Sci; 2009 Dec; 1182():97-110. PubMed ID: 20074279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.
    Ding C; Xu J; Li J
    Curr Opin Investig Drugs; 2008 May; 9(5):515-22. PubMed ID: 18465662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of ustekinumab in autoimmune disease.
    Ryan C; Thrash B; Warren RB; Menter A
    Expert Opin Biol Ther; 2010 Apr; 10(4):587-604. PubMed ID: 20218921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
    Gandhi M; Alwawi E; Gordon KB
    Semin Cutan Med Surg; 2010 Mar; 29(1):48-52. PubMed ID: 20430307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel biologic therapies in development targeting IL-12/IL-23.
    van de Kerkhof PC
    J Eur Acad Dermatol Venereol; 2010 Oct; 24 Suppl 6():5-9. PubMed ID: 20831703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-12, interleukin-23, and psoriasis: current prospects.
    Torti DC; Feldman SR
    J Am Acad Dermatol; 2007 Dec; 57(6):1059-68. PubMed ID: 17706835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuvion. Protein Design Labs.
    Trajkovic V
    Curr Opin Investig Drugs; 2002 Mar; 3(3):411-4. PubMed ID: 12054088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis.
    Zaghi D; Krueger GG; Callis Duffin K
    J Drugs Dermatol; 2012 Feb; 11(2):160-7. PubMed ID: 22270196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of psoriasis with interleukin-12/23 monoclonal antibody: a systematic review.
    Wu Y; Chen J; Li YH; Ma GZ; Chen JZ; Gao XH; Chen HD
    Eur J Dermatol; 2012; 22(1):72-82. PubMed ID: 22266126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug evaluation: zanolimumab, a human monoclonal antibody targeted against CD4.
    Assaf C; Sterry W
    Curr Opin Mol Ther; 2007 Apr; 9(2):197-203. PubMed ID: 17458175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-23: a key cytokine in inflammatory diseases.
    Duvallet E; Semerano L; Assier E; Falgarone G; Boissier MC
    Ann Med; 2011 Nov; 43(7):503-11. PubMed ID: 21585245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-IL-12/23 in Crohn's disease: bench and bedside.
    Niederreiter L; Adolph TE; Kaser A
    Curr Drug Targets; 2013 Nov; 14(12):1379-84. PubMed ID: 24138637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.
    Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
    Ann N Y Acad Sci; 2012 Aug; 1263():1-12. PubMed ID: 22823582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
    Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
    Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis.
    Guan Q; Ma Y; Hillman CL; Ma A; Zhou G; Qing G; Peng Z
    Vaccine; 2009 Nov; 27(50):7096-104. PubMed ID: 19786142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?
    Griffiths CE; Girolomoni G
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():2-8. PubMed ID: 22758911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis.
    Kasper LH; Everitt D; Leist TP; Ryan KA; Mascelli MA; Johnson K; Raychaudhuri A; Vollmer T;
    Curr Med Res Opin; 2006 Sep; 22(9):1671-8. PubMed ID: 16968570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?
    Zhang Z; Hinrichs DJ; Lu H; Chen H; Zhong W; Kolls JK
    Int Immunopharmacol; 2007 Apr; 7(4):409-16. PubMed ID: 17321463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.